Oppenheimer raised the firm’s price target on Immunocore (IMCR) to $86 from $85 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, the company announced strong Q1 sales for KIMMTRAK, with revenue of $93.9M vs. OPCO/Consensus of $88M/$87M, +12% from the prior quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings Reports Strong Q1 2025 Performance
- Immunocore price target lowered to $52 from $66 at Barclays
- Immunocore Holdings: Strong Sales Growth and Financial Position Justify Buy Rating
- Immunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation
- Immunocore reports Q1 EPS 10c, consensus (40c)